ArticleNeuroepidemiology2023
Burden of Parkinson Disease in China, 1990-2019: Findings from the 2019 Global Burden of Disease Study.
Article in Neuroepidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Levodopa and Plant-Derived Bioactive Compounds in Parkinson's Disease: Mechanisms, Efficacy, and Future Perspectives.CNS neuroscience & therapeutics · 2025Pooled it
- Global trends of early-onset Parkinson's disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.Frontiers in neurology · 2025Pooled it
- Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson's disease patients with a matching adjusted indirect comparison.Scientific reports · 2025Trial
- North-South asymmetry of Parkinson's disease mortality in Brazil between 2009 and 2023: a spatial analysis.Scientific reports · 2026Article
- Classifying drug-related problems of neurodegenerative diseases in the physician-pharmacist joint clinic of neurology: an application of the PCNE method.BMC geriatrics · 2026Article
- Exploring eye movement abnormalities as objective biomarkers for Parkinson's disease utilizing virtual reality-based eye tracking.BMC neurology · 2026Article
- In vivo and in vitro perspectives in Parkinson's disease: Mechanisms and the role of phytomedicine.Journal of food and drug analysis · 2025Review
- Illness acceptance and community self-efficacy mediate the relationship between social isolation and loneliness among elderly people with parkinson's disease.Scientific reports · 2025Article
- Reduced Risk of Benign Paroxysmal Positional Vertigo in Patients with Parkinson's Disease: A Nationwide Korean Cohort Study.Healthcare (Basel, Switzerland) · 2025Article
- NDDRF 2.0: An update and expansion of risk factor knowledge base for personalized prevention of neurodegenerative diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Lysophosphatidylcholine promoting α-Synuclein aggregation in Parkinson's disease: disrupting GCase glycosylation and lysosomal α-Synuclein degradation.NPJ Parkinson's disease · 2025Article
- Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021.BMJ (Clinical research ed.) · 2025Article
- Improving reliability of movement assessment in Parkinson's disease using computer vision-based automated severity estimation.Journal of Parkinson's disease · 2025Article
- Insomnia in Parkinson's Disease: Causes, Consequences, and Therapeutic Approaches.Molecular neurobiology · 2025Review
- Prevalence, associated factors and impact of mild cognitive impairment in hospitalized older adults with Parkinson's disease: a cross-sectional study.Frontiers in aging neuroscience · 2025Article
- Temporal and geographical dynamics of early-onset Parkinson's disease burden: insights from the Global Burden of Disease Study 2021.Frontiers in neurology · 2025Article
- Mapping the global burden of early-onset Parkinson's disease: socioeconomic and regional inequalities from the Global Burden of Disease Study 2021.Frontiers in public health · 2025Article
- Evaluation of damage discrimination in dopaminergic neurons using dopamine transporter PET tracer [EJNMMI research · 2024Article
- Analysis of mortality in Parkinson disease in China: Exploration of recent and future trends.Aging medicine (Milton (N.S.W)) · 2024Article
- Disease burden of Parkinson's disease in China and its provinces from 1990 to 2021: findings from the global burden of disease study 2021.The Lancet regional health. Western Pacific · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChina has the most people with Parkinson disease (PD) in the world and is estimated to have over half of the worldwide PD population. The objective of this study was to analyze the corresponding burden of PD in China for the past decades.
methodData on disease burden related to PD in China were retrieved from the Global Burden of Disease (GBD) 2019 study. The estimated annual percentage changes (EAPCs) were calculated to assess temporal trends, and the ratio of years lived with disability (YLDs) to disability-adjusted life years (DALYs) was used as an index to evaluate the healthcare system.
resultNationally, the burden of PD increased from 1990 to 2019. Although the age-standardized incidence rate (ASIR) increased, the age-standardized death rate (ASDR) and age-standardized DALY rate both decreased. Age-standardized rates of PD in males remained higher than those in females, but trends in ASDR and the age-standardized DALY rate for females showed a pronounced decrease. The most remarkable increase in the ASIR was in individuals aged 45-49 years, with an EAPC of 1.74 (95% confidence interval, 1.26-2.21). The YLDs:DALYs ratio continuously increased compared with global figures and even with countries with high sociodemographic index (SDI).
conclusionAlthough ASDR and age-standardized DALY rates for PD have been declining, the burden of PD still needs attention as the total numbers have increased over the period. Generally, the greater burden of PD was in males. A sound health system with services tailored to PD continues to be required in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.